CompletedPHASE1, PHASE2NCT04254939
A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
Studying Gastrointestinal stromal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CStone Pharmaceuticals
- Principal Investigator
- Lin SHEN, MDPeking University Cancer Hospital & Institute
- Intervention
- CS3007 (BLU-285)(drug)
- Enrollment
- 65 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2023
Study locations (16)
- Beijing Cancer Hospital, Beijing, Beijing Municipality, China
- Chinese PLA General Hospital, Beijing, Beijing Municipality, China
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
- Fujian Medical University Union Hospital, Fuzhou, Fujian, China
- The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
- The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
- Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
- Wuhan Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
- The First Affiliated Hospital of Nanchang Medical University, Nanchang, Jiangxi, China
- Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
- Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
- Fudan University Zhongshan Hospital (General Surgery Department), Shanghai, Shanghai Municipality, China
- Fudan University Zhongshan Hospital (Internal Tumor Department), Shanghai, Shanghai Municipality, China
- Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality, China
- Xinjiang Medical University Cancer Hospital, Ürümqi, Xinjiang, China
- +1 more locations on ClinicalTrials.gov
Collaborators
Blueprint Medicines Corporation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04254939 on ClinicalTrials.govOther trials for Gastrointestinal stromal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07171203Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorUniversity of California, San Diego
- RECRUITINGNANCT07405125Safety of Robotic Surgery for GISTs at Special Anatomic SitesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE3NCT07218926A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyGlaxoSmithKline
- RECRUITINGPHASE1NCT06655246A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Kura Oncology, Inc.
- RECRUITINGNANCT06926374Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic SurgeryChinese University of Hong Kong
- RECRUITINGNANCT07411118RCT of EFTR Versus STER for GIST TreatmentChinese University of Hong Kong
- RECRUITINGPHASE1, PHASE2NCT06630234A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)Deciphera Pharmaceuticals, LLC
- RECRUITINGPHASE3NCT06640361A Study of Olverembatinib in SDH-deficient GIST.Ascentage Pharma Group Inc.